Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
εPA44
- Development stage
- Phase 2
- Lead developer
- Third Military Medical University
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
εPA44 is a therapeutic vaccine candidate developed by the First Hospital of Peking University for the treatment of chronic hepatitis B (CHB). It is a recombinant fusion protein that combines the Hepatitis B virus e antigen (HBeAg) with the translocation domain (Domain II) of Pseudomonas aeruginosa exotoxin A (PEA). The vaccine is designed to overcome the immune tolerance characteristic of CHB by utilizing the PEA domain to facilitate the entry of HBeAg into the MHC class I antigen processing pathway of antigen-presenting cells. This mechanism aims to stimulate a robust HBeAg-specific CD8+ T-cell response, which is typically deficient in chronic carriers, to help clear the virus. Clinical trials have evaluated its efficacy in inducing HBeAg seroconversion and reducing HBV DNA levels in patients with chronic hepatitis B.
- Other names
- Epsilon-PA44Epsilon-PA-44Epsilon-PA 44HBeAg-PEA fusion protein
02
Targets
Human leukocyte antigen class I and class II peptide-binding grooves presenting HBV PreS2 and core epitopesHBV-specific TCR (Hepatitis B virus PreS2/core-specific T-cell receptor)
Beyond the preview
Go deeper on εPA44.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on εPA44.